Patient perspective on cancer care funding
Improvement in survival (a.k.a. efficiacy) clearly are important, but what other factors matter? According to a systematic literature review by MacLeod, Harris and Mahal (2016), these factors include: patients favour funding for cancer medicines that improve health outcomes demonstrated by ‘clinical efficacy’ [Oh et al.], ‘prolonged survival’ [Goldman et al., Seabury et al. Lakdawalla et al.] and/or…